share_log

Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2024 Financial Results

Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2024 Financial Results

吉利德科学 | 8-K:吉利德科学公布2024年第二季财务业绩
美股SEC公告 ·  2024/08/09 04:39

Moomoo AI 已提取核心信息

Gilead Sciences reported Q2 2024 total revenue of $7.0 billion, up 5% year-over-year, with product sales excluding Veklury increasing 6% to $6.7 billion. HIV sales grew 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenue rose 15% to $841 million, with Trodelvy sales up 23% to $320 million.Operating income reached $2.6 billion, with GAAP diluted EPS of $1.29 compared to $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues. Cash and equivalents stood at $2.8 billion as of June 30, down from $8.4 billion at year-end 2023, primarily due to the $3.9 billion CymaBay acquisition.The company maintained its full-year 2024 product sales guidance of $27.1-27.5 billion, with product sales excluding Veklury projected at $25.8-26.2 billion. The non-GAAP EPS guidance was raised to $3.60-3.90 from the previous $3.45-3.85 range.
Gilead Sciences reported Q2 2024 total revenue of $7.0 billion, up 5% year-over-year, with product sales excluding Veklury increasing 6% to $6.7 billion. HIV sales grew 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenue rose 15% to $841 million, with Trodelvy sales up 23% to $320 million.Operating income reached $2.6 billion, with GAAP diluted EPS of $1.29 compared to $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues. Cash and equivalents stood at $2.8 billion as of June 30, down from $8.4 billion at year-end 2023, primarily due to the $3.9 billion CymaBay acquisition.The company maintained its full-year 2024 product sales guidance of $27.1-27.5 billion, with product sales excluding Veklury projected at $25.8-26.2 billion. The non-GAAP EPS guidance was raised to $3.60-3.90 from the previous $3.45-3.85 range.
吉利德科学报告2024年第二季度总营业收入为70亿美元,同比增长5%,不包括Veklury的产品销售增长6%至67亿美元。HIV销售增长3%至47亿美元,主要得益于Biktarvy增长8%至32亿美元。肿瘤学收入增长15%至84100万美元,Trodelvy销售增长23%至32000万美元。营业收入达到26亿美元,GAAP摊薄后每股收益为1.29美元,而2023年第二季度为0.83美元。改善主要得益于更低的营业费用和更高的营业收入。截至6月30日,公司现金及现金等价物为28亿美元,低于2023年年底的84亿美元,主要由于39亿美元的CymaBay收购。公司维持2024年整年产品销售指导为271-275亿美元,不包括Veklury的产品销售预计为258-262亿美元。非GAAP每股收益指导上调至3.60-3.90美元,之前为3.45-3.85的区间。
吉利德科学报告2024年第二季度总营业收入为70亿美元,同比增长5%,不包括Veklury的产品销售增长6%至67亿美元。HIV销售增长3%至47亿美元,主要得益于Biktarvy增长8%至32亿美元。肿瘤学收入增长15%至84100万美元,Trodelvy销售增长23%至32000万美元。营业收入达到26亿美元,GAAP摊薄后每股收益为1.29美元,而2023年第二季度为0.83美元。改善主要得益于更低的营业费用和更高的营业收入。截至6月30日,公司现金及现金等价物为28亿美元,低于2023年年底的84亿美元,主要由于39亿美元的CymaBay收购。公司维持2024年整年产品销售指导为271-275亿美元,不包括Veklury的产品销售预计为258-262亿美元。非GAAP每股收益指导上调至3.60-3.90美元,之前为3.45-3.85的区间。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息